Skip to content
Menu

Nuvation Bio Inc. NUVB

Full chart Compare
Set alert

Price alert · NUVB

All alert types
3.81 USD +0.03 (+0.79%)

Regular-session close

3.81 0.00 0.00%

Pre-market · Nov 20, 7:59 AM ET

3.71 Day range 4.03
3.71 52-week range 9.75
YTD
-57.48%
1 year
-45.65%

5D -0.17 (-4.27%)

3.804FriMonTueWedThu3.81
Market cap
1.34B
Revenue (ttm)
201.73M
Profit margin
-67.38%
EPS (ttm)
-0.39
Shares out
352.02M
Forward P/E
-47.63
YTD return
-57.48%
1-year return
-45.65%
50-day average
4.96
200-day average
5.30
Volume
9.92M
Avg volume
5.23M
Open
3.77
Previous close
3.78
Day's range
3.71 – 4.03
52-week range
3.71 – 9.75
Beta
1.73
Analysts
Strong Buy
Price target
12.45 (+226.9%)
Earnings date
Mar 1, 2027

Key statistics

Enterprise value
1.14B
Price / sales
6.67
Price / book
5.90
Revenue growth
242.60%
Free cash flow
-76.06M
Total cash
663.37M
Total debt
468.12M
Return on equity
-49.09%
Short % of float
28.82%

Fundamental scorecard

5 of 25 checks passed on NUVB’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 0 of 5
  • Growth 2 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
NUVB Revenue — quarterly 44.95M
NUVB Net income — quarterly -41.90M
NUVB EPS — quarterly -0.12

Earnings

NUVB recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 1, 2027Dec 30, 2026-0.11———
Nov 4, 2026Sep 30, 2026-0.12374-0.120.00+3.02%
Aug 6, 2026Jun 30, 2026-0.14166-0.15-0.01-5.89%
May 4, 2026Mar 31, 2026-0.028040.01+0.04+135.66%
Mar 2, 2026Dec 31, 2025-0.11-0.110.000.00%
Nov 3, 2025Sep 30, 2025-0.17-0.16+0.01+5.88%

Upgrades / downgrades

NUVB analyst upgrades and downgrades
DateFirmActionFromTo
Nov 17, 2026HC Wainwright & Co.reitBuyBuy
Nov 5, 2026RBC CapitalmainOutperformOutperform
Sep 30, 2026Citigroupinit—Buy
Sep 16, 2026CitizensreitMarket OutperformMarket Outperform
Sep 16, 2026WedbushreitOutperformOutperform
Aug 21, 2026Cantor Fitzgeraldinit—Overweight

About Nuvation Bio Inc.

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on NUVB — it syncs with the Stock Master app.

Insider holders

NUVB insider holders
InsiderRelationLatest transactionDateShares held
HANLEY DAVID CChief Technology OfficerConversion of Exercise of derivative securityNov 18, 202524,000
HATTERSLEY GARYOfficerConversion of Exercise of derivative securityAug 18, 20260
HUNG DAVID TChief Executive OfficerPurchaseJun 15, 202559,281,100
LIU DONGFANGOfficerConversion of Exercise of derivative securityApr 16, 202618,000
MAKUNJE MOSESOfficerStock Award(Grant)Feb 26, 202668,137
MARKEL STACYOfficerConversion of Exercise of derivative securityJun 22, 202632,591

Institution ownership

NUVB institution ownership
Holder% heldSharesValueReported
FMR, LLC14.92%52,668,484200.67MSep 29, 2026
Blackrock Inc.8.19%28,924,444110.20MSep 29, 2026
Decheng Capital LLC7.35%25,954,43998.89MSep 29, 2026
Vanguard Capital Management LLC3.44%12,152,90346.30MSep 29, 2026
Laurion Capital Management, LP2.18%7,697,27229.33MSep 29, 2026
State Street Corporation2.15%7,596,20928.94MSep 29, 2026

Fund ownership

NUVB fund ownership
Holder% heldSharesValueReported
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund5.02%17,725,17567.53MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.51%8,849,32933.72MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF1.85%6,523,17224.85MSep 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund1.41%4,993,37719.02MSep 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund1.29%4,568,60117.41MSep 29, 2026
American Century Mutual Funds, Inc.-Small Cap Growth Fund0.97%3,423,82313.04MSep 29, 2026